pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 43 | Non-oncology: 27 Oncology: 16 |
| Under Consideration for Negotiation | 22 | Non-oncology: 11 Oncology: 11 |
| Completed Negotiations | 909 | With Letter of Intent: 784 Without agreement: 125 |
| Negotiations That Were Not Pursued | 113 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Braftovi | Pfizer Canada ULC | in combination with cetuximab and chemotherapy, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test. | |
| Welireg | Merck Canada Inc. | For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). | |
| Qalsody | Biogen Canada Inc. | Amyotrophic Lateral Sclerosis (ALS) | |
| Hepcludex | Gilead Sciences Canada Inc. | Chronic hepatitis delta virus (HDV) infection | |
| Okedi | Bausch Health, Canada Inc. | Schizophrenia in Adults | |
| Enhertu | AstraZeneca Canada Inc. | For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the meta | |
| Nemluvio | Galderma Canada Inc. | Prurigo nodularis | |
| Nemluvio | Galderma Canada Inc. | For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy. | |
| Andembry | CSL Behring Canada Inc. | Hereditary Angioedema |